Role of some members of chemokine/cytokine network in the pathogenesis of thalassemia and sickle cell hemoglobinopathies: a mini review
AbstractThe word of hemoglobinopathy is described for an array of disorders that affecting hemoglobin (Hb) functions. Hb is a molecule with 68  kDa molecular weight, serving as oxygen carrying metalloprotein. Hemoglobinopathy includes a wide range of Hb structural deficits varying from thalassemia to sickle cell disease. Cyto-chemokine network members are pivotally involved in the pathogenesis of hemoglobinopathies, however, the exact rol e of these mediators in the development of these disorders yet to be well addressed. Cytokines and chemokines are generated by inflamed endothelial cells that promote the expression ...
Source: Experimental Hematology and Oncology - September 11, 2019 Category: Cancer & Oncology Source Type: research

Cabozantinib and apixaban: an hitherto unreported interaction
We describe, for the first time, a case of neutropenia and thrombocytopenia in a patient in treatment with cabozantinib, a novel anticancer treatment used in metastatic renal cell carcinoma, and apixaban with promptly resumption of the toxicity after the interruption of cabozantinib. This case suggest a possible interaction between these two pharmaceutical agents, which merit caution considering the spreading of the two drugs. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - September 11, 2019 Category: Cancer & Oncology Source Type: research

Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma
ConclusionsPD-1 inhibitors are now widely used in a multitude of cancer types including melanoma, advanced non-small cell lung cancer, metastatic renal cell carcinoma, and Hodgkin lymphoma amongst others. While these agents are often well tolerated, they are associated with a unique profile of immune-related toxicities that can cause significant morbidity and mortality. Education of both patients and healthcare providers is essential for diagnosis and treatment of these adverse events early in their course. This case highlights the uncommon but potentially serious PD-1-associated toxicity of myopathy and rhabdomyolysis alo...
Source: Experimental Hematology and Oncology - September 10, 2019 Category: Cancer & Oncology Source Type: research

Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
AbstractNon-small cell lung cancer (NSCLC) has been threatening human health for years. Cytotoxicity-based chemotherapy seems to reach plateau in NSCLC treatment. Immunotherapy with immune checkpoint inhibitors (ICIs) against programmed cell death 1 (PD-1/L1) axis are to provide long-term survival benefits for wild-type advanced NSCLC patients with acceptable adverse effects. Though beneficiary population is limited from monotherapy, combination strategies are expanding indicators. Retrospective evidences suggested ICIs are also potentially useful for brain metastasis. Furthermore, the combination of ICIs and surgery are t...
Source: Experimental Hematology and Oncology - August 22, 2019 Category: Cancer & Oncology Source Type: research

A novel RNA variant of human concentrative nucleoside transporter 1 (hCNT1) that is a potential cancer biomarker
ConclusionWe have identified a novel intron retaining and exon skipping splice variant of the hCNT1  nucleoside transporter, and designated it hCNT1-IR, which has a similar tissue expression distribution as the normal hCNT1 variant, but unlike the normal transcript, hCNT1-IR is overexpressed in some cancers and may serve as a potential cancer biomarker. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - August 22, 2019 Category: Cancer & Oncology Source Type: research

Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)
ConclusionsWe conclude that mutations inTET2 may contribute to clonal expansion in exceptional cases of PNH. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - August 21, 2019 Category: Cancer & Oncology Source Type: research

Frontline therapies for untreated chronic lymphoid leukemia
AbstractTherapy for chronic myeloid leukemia (CLL) is going through a major paradigm shift. Combination chemoimmunotherapy regimens have been the frontline therapies for CLL, whereas chlorambucil remained the standard frontline therapy for older patients (65  years or older) with CLL until recently. Monoclonal antibodies including rituximab, ofatumumab and obinutuzumab have been used for CLL therapy. Novel immunotherapeutics with chimeric antigen receptor (CAR) engineered T cells is rapidly migrating to clinical applications. Targeted therapies with sm all molecule inhibitors against Bruton tyrosine kinase (BTK) such ...
Source: Experimental Hematology and Oncology - August 17, 2019 Category: Cancer & Oncology Source Type: research

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
ConclusionIbrutinib negatively affects anti-CD20 induced cell death in MCL, not reversed by lenalidomide. Explorations of sequential administration and selective BTK-inhibitors may reveal the optimal combination of novel agents in MCL. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - August 6, 2019 Category: Cancer & Oncology Source Type: research

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
ConclusionsThe total costs incurred by a patient over a 48-month period following treatment initiation with NIVO  + IPI are lower when compared with patients initiating monotherapies; further, the cost advantage is seen to be increasing over time. The clinical benefits offered by the regimen are thus supplemented by a cost advantage, as patients receiving either monotherapy treatment experience faster prog ression and, consequently, higher subsequent treatment costs. (Note: The cost results reported here are specific to the UK, and Germany, and may not be generalizable to other geographies). (Source: Experime...
Source: Experimental Hematology and Oncology - July 3, 2019 Category: Cancer & Oncology Source Type: research

An expanded biomarker panel for the detection of prostate cancer from urine DNA
ConclusionsThis study shows that large marker panels can be analyzed from urine DNA without loss of sensitivity or specificity. Using 32 markers improved the stratification of patients undergoing screening for PCA particularly for patients below the 10of32 threshold. The results show the utility of larger biomarker panels for PCA diagnosis and suggest that the development of the panels needed to monitor disease progression could be successfully accomplished. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - June 27, 2019 Category: Cancer & Oncology Source Type: research

Novel GTF2I – PDGFRB and IKZF1 – TYW1 fusions in pediatric leukemia with normal karyotype
ConclusionsThe examined pediatric leukemia is a Ph-like ALL which carries novelGTF2I–PDGFRB andIKZF1–TYW1 fusion genes together with additional submicroscopic deletions. Because hematologic neoplasms withPDGFRB-fusion genes can be treated with tyrosine kinase inhibitors, the detection of such novel fusions may be clinically important. Since theGTF2I–PDGFRB could be detected only after molecular studies of the leukemic cells, further investigations of ALL-cases, perhaps especially but not exclusively with a normal karyotype, are needed in order to determine the frequency ofGTF2I–PDGFRB in leukemia, a...
Source: Experimental Hematology and Oncology - May 29, 2019 Category: Cancer & Oncology Source Type: research

NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children
ConclusionsThe data suggest thatNRAS andKRAS polymorphisms are irrelevant to hepatoblastoma susceptibility among Chinese population. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - May 9, 2019 Category: Cancer & Oncology Source Type: research

Development of a high resolution melting analysis assay for rapid identification of JAK2 V617F missense mutation and its validation
ConclusionsFor HRM analysis is cost-effective and beside that it is enzyme independence method also this method able to show amount of the mutant allele carried in samples and it ’s helpful for treatments follow-up and determining MRD for them. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - April 30, 2019 Category: Cancer & Oncology Source Type: research

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
AbstractPatients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents (HMA). Stem cell transplantation is the only effective salvage therapy, for which only a limited number of patients are eligible due to age and comorbidity. Combination therapy of venetoclax and azacitidine (5-AZA) seems to be a promising approach in myeloid malignancies, but data from patients with HMA failure are lacking. Furthermore, a considerable concern of combination regimens in elderly AML and MDS patients is the toxicity on the remaining healthy hemato...
Source: Experimental Hematology and Oncology - April 16, 2019 Category: Cancer & Oncology Source Type: research

Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation
ConclusionsMulti-organ failure represents a rare but potentially fatal outcome of immune checkpoint blockade in patients receiving allogeneic stem cell grafts. Nivolumab may induce atypical immune-mediated tissue inflammation and damage, such as the extensive muscular polymyositis described here in a patient with Hodgkin lymphoma. Nivolumab might also worsen GVHD symptoms in the context of allogeneic stem cell transplantation. Irrespective of the actual pathological mechanisms, clinicians should be alerted to these fatal drug-related toxicities. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - March 28, 2019 Category: Cancer & Oncology Source Type: research

The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994 –2016
AbstractBackgroundAutologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality.MethodsAll 433 lymphoma patients who underwent ASCT for lymphoma at Karolinska Huddinge 1994 –2016 were investigated, including CD34+ cell amounts, medications, infectious and other complications, intensive care, longitudinal laboratory values, and secondary myeloid neoplasia.ResultsThe 100-day non-relapse and overall mortalities were 5.6% and 7.2%. Stem-cell harvests  
Source: Experimental Hematology and Oncology - March 18, 2019 Category: Cancer & Oncology Source Type: research

Thyroid dysfunction from inhibitor of fibroblast growth factor receptor
ConclusionFurther reports and studies will be needed to confirm the relationship between AZD4547 and hypothyroidism. Based on this observation and possible mechanisms for thyroid dysfunction discussed in this paper, routine thyroid function monitoring in patients receiving FGFR inhibitor should be considered. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - February 18, 2019 Category: Cancer & Oncology Source Type: research

Immunotherapy in extensive small cell lung cancer
AbstractSmall cell lung cancer which constitutes about 15% of lung cancers is pathobiologically and clinically distinct from non small cell cancer. Histologically it is characterized by small cells with scant cytoplasm, absent or inconspicuous nucleoli, extensive necrosis, and expresses neuroendocrine markers. It is on a spectrum of neuroendocrine cancer that extend from typical carcinoids to large cell to small cell cancer. Clinically it behaves in a more malignant fashion with a rapid doubling time, early metastasis. They respond rapidly to cytotoxic treatment however tend to develop resistance soon. Immunotherapy with c...
Source: Experimental Hematology and Oncology - February 4, 2019 Category: Cancer & Oncology Source Type: research

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
We report a case of Bortezomib-induced SIADH, in whom the use of tolvaptan, a vasopressin receptor-2 antagonist, permitted the continuation of triple combination anti-MM therapy with lenalidomide, Bortezomib and dexamethasone (RVD) in a female with aggressive disease, without the development of hyponatremia. Our patient had a rapid relapse, in which the use of Bortezomib as part of an RVD regimen was life-saving. The use of tolvaptan allowed continuation of therapy that is usually halted in other similarly reported cases. This case highlights the possible use of vaptans, which allows an aquaresis to occur by blocking the a...
Source: Experimental Hematology and Oncology - February 1, 2019 Category: Cancer & Oncology Source Type: research

Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia
In this study, we conducted a retrospective study in adult AML patients with newly diagnosed with de novo AML who did not undergo HSCT, to study long term relapse free survival (RFS) and overall survival (OS) after consolidation chemotherapy.MethodsWe recruited 141 consecutive AML patients during January 2010 –June 2017, the patients received induction chemotherapy with standard dose Ara-C and Idarubicin (7 + 3 or 5 + 2 regimen) followed by intermediate (IDAC) or high dose Ara-c (HiDAC) consolidation therapy.ResultsNormal karyotype, complex, favorable, intermediate and adverse chromosomal ...
Source: Experimental Hematology and Oncology - January 30, 2019 Category: Cancer & Oncology Source Type: research

Mantle cell lymphoma and its management: where are we now?
AbstractMantle cell lymphoma is a relatively new recognized hematological malignant disease, comprising of 2.5 –6% non-Hodgkin’s lymphomas. The complexity of its clinical presentations (nodular pattern, diffuse pattern, and blastoid variant), variety in disease progression, and treatment response, make this disease a research focus to both experimental oncology and clinical oncology. Overexpression of cy clin D1 and chromosome t(11,14) translocation are the known molecular biomarkers of this disease. Mantle cell international prognostic index (MIPI), ki-67 proliferation index, andTP53 mutation are emerging as t...
Source: Experimental Hematology and Oncology - January 30, 2019 Category: Cancer & Oncology Source Type: research

Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant
AbstractBackgroundSecond allogeneic hematopoietic stem cell transplant (HCT) remains as an option for disease relapse after initial HCT.MethodsWe analyzed retrospectively the outcomes of 65 consecutive patients who underwent a second HCT for disease relapse at the University of Chicago. Univariate and multivariate analysis were conducted, and a scoring system was generated to select the patients who would benefit second HCT.ResultsAll except four patients received T cell depleted (TCD) first HCT. The majority of patients had AML (n  = 47) and high risk MDS (n = 5). The median age at second HCT w...
Source: Experimental Hematology and Oncology - January 3, 2019 Category: Cancer & Oncology Source Type: research

Methylome of human senescent hematopoietic progenitors
AbstractSenescence, a state of permanent cell cycle arrest, can be induced by DNA damage. This process, which was initially described in fibroblasts, is now recognized to occur in stem cells. It has been well characterized in cell lines, but there is currently very limited data available on human senescence in vivo. We recently reported that the expression of transposable elements (TE), including endogenous retroviruses, was up-regulated along with inflammatory genes in human senescent hematopoietic stem and progenitor cells (HSPCs) in vivo. The mechanism of regulation of TE expression is not completely understood, but cha...
Source: Experimental Hematology and Oncology - December 21, 2018 Category: Cancer & Oncology Source Type: research

The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia
AbstractBackgroundThe evolution of molecular studies in myeloproliferative neoplasms (MPN) has enlightened us the understanding of this complex disease consisting of polycythaemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The epidemiology is well described in the western world but not in Asian countries like Malaysia.Materials and methodsThis retrospective national registry of MPN was conducted from year 2009 to 2015 in Malaysia.ResultsA total of 1010 patients were registered over a period of 5  years. The mean age was 54 years with male predominance. The ethnic distribution revea...
Source: Experimental Hematology and Oncology - December 17, 2018 Category: Cancer & Oncology Source Type: research

Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
AbstractOrganoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulates organ development and human diseases, such as infectious diseases, genetic abnormality and even cancers. In addition, organoids can more accurately predict drug responses, and serve as an excellent platform for drug development, including efficacy evaluation, toxicity testing and pharmacokinetics analysis. Furthermore, organoids can also be exploited to explore the possible optimized treatment strategies for each individual patient. Besides, org...
Source: Experimental Hematology and Oncology - December 5, 2018 Category: Cancer & Oncology Source Type: research

Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi Arabia
ConclusionsArm switching to a more intensive protocol had mixed results. Assigning patients by end-of-induction MRD-risk alone did not reflect response kinetics of the different NCI-risk groups. Although late treatment intensification improved outcomes of NCI-SR patients with positive MRD at end-of-induction, further refinement is needed to improve outcomes of NCI-HR with SER. Integration of NCI-risk group with specific MRD value and time point allows more refined treatment stratification.Trial Registration Protocols were approved by King Abdullah International Medical Research Center and Ethics Review Committee RC08053J (...
Source: Experimental Hematology and Oncology - November 19, 2018 Category: Cancer & Oncology Source Type: research

The role of neoantigen in immune checkpoint blockade therapy
AbstractImmune checkpoint inhibitor induces tumor rejection by activated host immune system. The anti-tumor immune response consists of capture, presentation, recognition of neoantigen, as well as subsequent killing of tumor cell. Due to the interdependence among this series of stepwise events, neoantigen profoundly influences the efficacy of anti-immune checkpoint therapy. Moreover, the neoantigen-specific T cell reactivity is the cornerstone of multiple immunotherapies. In fact, several strategies targeting neoantigen have been attempted for synergetic effect with immune checkpoint inhibitor. Increasing neoantigen presen...
Source: Experimental Hematology and Oncology - November 16, 2018 Category: Cancer & Oncology Source Type: research

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth
ConclusionIn vitro, daratumumab is not toxic to mobilized CD34+  progenitor cells from myeloma patients. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - October 16, 2018 Category: Cancer & Oncology Source Type: research

Early detection of transformation to BPDCN in a patient with MDS
ConclusionThe case demonstrates that minimal transformative disease of BPDCN may be detectable in patients with MDS well before fulminant progression. Early detection of emerging leukemic clones may allow for alternative monitoring and treatment considerations. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - October 6, 2018 Category: Cancer & Oncology Source Type: research

Induction of anti-leukemic responses by stimulation of leukemic CD3+ cells with allogeneic stimulator cells
ConclusionsThese results indicate that CD3+ cells from leukemic patients are capable of generating anti-leukemic responses when stimulated with unrelated allogeneic cells. This model can be used to identify approaches using alloreactive responses by patient lymphocytes to enhance in vivo anti-leukemic responses. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - October 4, 2018 Category: Cancer & Oncology Source Type: research

Mechanisms for estrogen receptor expression in human cancer
AbstractEstrogen is a steroid hormone that has critical roles in reproductive development, bone homeostasis, cardiovascular remodeling and brain functions. However, estrogen also promotes mammary, ovarian and endometrial tumorigenesis. Estrogen antagonists and drugs that reduce estrogen biosynthesis have become highly successful therapeutic agents for breast cancer patients. The effects of estrogen are largely mediated by estrogen receptor (ER) α and ERβ, which are members of the nuclear receptor superfamily of transcription factors. The mechanisms underlying the aberrant expression of ER in breast cancer and ot...
Source: Experimental Hematology and Oncology - September 19, 2018 Category: Cancer & Oncology Source Type: research

Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin
ConclusionsThe data suggest a significant temporal pattern of HIA in outpatients undergoing HD using unfractionated heparin. Positive HIA was not found to be significantly associated with thrombocytopenia or thrombosis risk in these patients. However, while not achieving statistical significance, subsequent  thrombotic events occurred most frequently in the strong positive HIA group (optical density> 1.000).  Further research into HIA and risk of thrombosis in this population is needed. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - September 14, 2018 Category: Cancer & Oncology Source Type: research

Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy
ConclusionsOverall, these results show that the proposed pegfilgrastim biosimilar is similar to Amgen ’s US-licensed and EU-approved pegfilgrastim reference products with regard to the clinical efficacy and safety endpoints assessed.Trial registration EMA: European Union Clinical Trials Register: (https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002678-21) Eudract # 2011-002678-21 Registered: 01/10/2012 (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - September 6, 2018 Category: Cancer & Oncology Source Type: research

Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
ConclusionThis case evidences that sequential personalized prescription of different TKIs may show promising efficacy in terms of survival and quality of life in MCC. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - September 6, 2018 Category: Cancer & Oncology Source Type: research

Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy
ConclusionsOverall, these results show that the proposed pegfilgrastim biosimilar is similar to Amgen ’s US-licensed and EU-approved pegfilgrastim reference products with regard to the clinical efficacy and safety endpoints assessed.Trial registration EMA: European Union Clinical Trials Register: (https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002678-21) Eudract # 2011-002678-21 Registered: 01/10/2012 (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - September 6, 2018 Category: Cancer & Oncology Source Type: research

Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
ConclusionThis case evidences that sequential personalized prescription of different TKIs may show promising efficacy in terms of survival and quality of life in MCC. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - September 6, 2018 Category: Cancer & Oncology Source Type: research

Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib
ConclusionsCutaneous squamous cell carcinoma is the 2nd most common skin cancer in humans and future investigation of ERBB2 targeted therapies may provide an effective treatment strategy for patients with mutations in the ERBB2/3 pathway. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - August 28, 2018 Category: Cancer & Oncology Source Type: research

The association of HLA-C alleles with multiple myeloma in Chinese patients
ConclusionTherefore, HLA-C region is a key risk locus for MM in Chinese population. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - August 23, 2018 Category: Cancer & Oncology Source Type: research

A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma
ConclusionThe study was prematurely stopped due to serious adverse events, in particular serious gastrointestinal complications and septicemia. The response data do not suggest any effect of clarithromycin when added to the VCD regimen. The combination of clarithromycin and bortezomib containing regimens is toxic and do not seem to offer extra anti-myeloma efficacy.Trial registration EudraCT (no. 2014-002187-32, registered 7 October 2014,https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002187-32/DK) and ClinicalTrials.gov (no NCT02573935, retrospectively registered 12 October 2015,https://www.clinicaltrials.gov/...
Source: Experimental Hematology and Oncology - August 13, 2018 Category: Cancer & Oncology Source Type: research

Emerging therapies in advanced hepatocellular carcinoma
ConclusionAdvanced HCC patients are difficult to treat with poor outcomes. After initial approval of sorafenib in 2007, we recently have multiple new agents that showed benefit and promising activity, and are set to change the landscape of HCC treatment. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Source Type: research

Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data
ConclusionsDespite consistent guideline recommendations for cytoreductive therapy in patients with high-risk PV, this analysis revealed that only a minority of these patients received cytoreductive medication. A notable proportion of high-risk patients with PV would likely benefit from a revised treatment plan that aligns with current guidelines. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - July 9, 2018 Category: Cancer & Oncology Source Type: research

Bullous hemorrhagic dermatosis is an under-recognized side effect of full dose low-molecular weight heparin: a case report and review of the literature
AbstractBullous hemorrhagic dermatosis (BHD) is a systemic side-effect of low molecular weight heparin, characterized by multiple intra-epidermal hemorrhages distant from the site of injection. There have been several small case series and literature reviews on BHD, but none have captured a complete set of reported patients. We sought to describe a case of BHD with late diagnosis and completely summarize the existing English and Spanish literature with searches of Pubmed, Scopus, Ovid Embase and Ovid Medline. After narrowing to 33 relevant reports, we describe 90 reported cases worldwide from 2004 to 2017, in addition to a...
Source: Experimental Hematology and Oncology - July 6, 2018 Category: Cancer & Oncology Source Type: research